+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Asia Pacific Artificial Intelligence In Cardiology Market Size, Share & Industry Analysis Report By Component, By Application,. By Medical Condition, By Country and Growth Forecast, 2025 - 2032

  • PDF Icon

    Report

  • 155 Pages
  • June 2025
  • Region: Asia Pacific
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
  • ID: 6108035
The Asia Pacific Artificial Intelligence In Cardiology Market is expected to witness market growth of 33.1% CAGR during the forecast period (2025-2032).

The China market dominated the Asia Pacific Artificial Intelligence In Cardiology Market by country in 2024, and is expected to continue to be a dominant market till 2032; thereby, achieving a market value of $997.7 million by 2032. The Japan market is registering a CAGR of 32.3% during 2025-2032. Additionally, the India market is expected to showcase a CAGR of 34.1% during 2025-2032.



The adoption of AI in cardiology is gaining momentum globally, driven by the increasing prevalence of CVDs, advancements in technology, and supportive regulatory frameworks. North America leads the market, with a robust healthcare infrastructure and rapid uptake of cutting-edge technologies. The region’s dominance is evident in strategic initiatives by key players, such as GE HealthCare’s launch of Caption AI in April 2024, a software designed for Vscan Air SL devices that provides real-time guidance for cardiac assessments and automated ejection fraction estimation.

The Asia Pacific region is emerging as a key growth area, fueled by rising cardiovascular disease rates and increasing investments in healthcare technology. Collaborations between technology companies and healthcare providers are accelerating adoption. A notable example is the partnership between the Cardiovascular Research Center Aalst and PMcardio in July 2023, which focuses on joint research to advance AI-powered cardiovascular diagnostics.

The Asia-Pacific region is witnessing rapid transformation in healthcare delivery, driven by technological innovation and the rising burden of cardiovascular diseases (CVDs). As one of the most populous and diverse regions globally, Asia-Pacific faces unique healthcare challenges, including varying levels of healthcare infrastructure, a mix of urban and rural populations, and growing incidences of heart-related ailments fueled by lifestyle changes, urbanization, and aging populations. Artificial Intelligence (AI) is increasingly recognized as a critical enabler to address these challenges in cardiology by improving diagnostic accuracy, streamlining clinical workflows, and enhancing patient monitoring and treatment outcomes.

The adoption of AI in cardiology across Asia-Pacific is propelled by increasing government initiatives promoting digital health transformation, expanding investments in AI research and development, and greater availability of digital health data. Countries in the region are leveraging AI technologies such as machine learning algorithms, deep learning for cardiac imaging, AI-enabled electrocardiogram (ECG) interpretation, and predictive analytics to manage cardiac conditions more effectively. Telecardiology and remote monitoring powered by AI are also gaining momentum, particularly in regions where access to specialized cardiology care is limited.

Market trends reveal widespread interest in AI-enabled ECG interpretation, wearable cardiac devices, and cloud-based platforms for cardiac data analytics. Regional collaborations and public-private partnerships are instrumental in fostering AI adoption. Multinational corporations often lead innovation efforts, with regional startups emerging gradually. Competition varies; in developed markets like Australia, the focus is on high-tech AI applications and integration with electronic health records, whereas in developing countries, affordability and scalability drive AI adoption. Regulatory frameworks are evolving, with a growing emphasis on data privacy and clinical validation. Thus, the  Asia-Pacific region presents significant growth opportunities for AI in Cardiology, supported by demographic needs and increasing digital healthcare investments.

List of Key Companies Profiled

  • IDOVEN S.L.
  • Ultromics Ltd.
  • CardiAI.Inc.
  • Tempus AI, Inc.
  • Koninklijke Philips N.V.
  • Cleerly, Inc.
  • Vista AI, Inc.
  • Viz.ai, Inc.
  • RSIP Vision Ltd.
  • GE HealthCare Technologies, Inc.

Market Report Segmentation

By Component

  • Hardware
  • Software
  • Services

By Application

  • Diagnosis
  • Prediction
  • Drug Discovery
  • Other Application

By Medical Condition

  • Ischemic Heart Disease /CAD
  • Cardiac Arrhythmias
  • Heart Failure
  • Other Medical Condition

By Country

  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific

Table of Contents

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Artificial Intelligence In Cardiology Market, by Component
1.4.2 Asia Pacific Artificial Intelligence In Cardiology Market, by Application
1.4.3 Asia Pacific Artificial Intelligence In Cardiology Market, by Medical Condition
1.4.4 Asia Pacific Artificial Intelligence In Cardiology Market, by Country
1.5 Methodology for the Research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.2.3 Market Opportunities
3.2.4 Market Challenges
Chapter 4. Competition Analysis - Global
4.1 Cardinal Matrix
4.2 Recent Industry Wide Strategic Developments
4.2.1 Partnerships, Collaborations and Agreements
4.2.2 Product Launches and Product Expansions
4.2.3 Acquisition and Mergers
4.3 Market Share Analysis, 2024
4.4 Top Winning Strategies
4.4.1 Key Leading Strategies: Percentage Distribution (2021-2025)
4.4.2 Key Strategic Move: (Product Launches and Product Expansions : 2021, Nov - 2025, Apr) Leading Players
4.5 Porter Five Forces Analysis
Chapter 5. Value Chain Analysis of Artificial Intelligence In Cardiology Market
5.1 Research & Development (R&D)
5.2 Data Acquisition & Management
5.3 Model Development & Training
5.4 Regulatory Approval & Certification
5.5 Product Integration & Deployment
5.6 Marketing & Sales
5.7 After-Sales Support & Feedback Loop
Chapter 6. Key Customer Criteria - Artificial Intelligence In Cardiology Market
6.1 Diagnostic Accuracy
6.2 Regulatory Compliance
6.3 Data Privacy and Security
6.4 Integration with Existing Healthcare Systems
6.5 Clinical Validation and Peer-Reviewed Evidence
6.6 Ease of Use and Interface Design
6.7 Real-Time Processing and Speed
6.8 Cost-Effectiveness and Return on Investment (ROI)
6.9 Continuous Learning and Model Updates
6.10. Vendor Support and Training Services
Chapter 7. Asia Pacific Artificial Intelligence In Cardiology Market by Component
7.1 Asia Pacific Hardware Market by Country
7.2 Asia Pacific Software Market by Country
7.3 Asia Pacific Services Market by Country
Chapter 8. Asia Pacific Artificial Intelligence In Cardiology Market by Application
8.1 Asia Pacific Diagnosis Market by Country
8.2 Asia Pacific Prediction Market by Country
8.3 Asia Pacific Drug Discovery Market by Country
8.4 Asia Pacific Other Application Market by Country
Chapter 9. Asia Pacific Artificial Intelligence In Cardiology Market by Medical Condition
9.1 Asia Pacific Ischemic Heart Disease /CAD Market by Country
9.2 Asia Pacific Cardiac Arrhythmias Market by Country
9.3 Asia Pacific Heart Failure Market by Country
9.4 Asia Pacific Other Medical Condition Market by Country
Chapter 10. Asia Pacific Artificial Intelligence In Cardiology Market by Country
10.1 China Artificial Intelligence In Cardiology Market
10.1.1 China Artificial Intelligence In Cardiology Market by Component
10.1.2 China Artificial Intelligence In Cardiology Market by Application
10.1.3 China Artificial Intelligence In Cardiology Market by Medical Condition
10.2 Japan Artificial Intelligence In Cardiology Market
10.2.1 Japan Artificial Intelligence In Cardiology Market by Component
10.2.2 Japan Artificial Intelligence In Cardiology Market by Application
10.2.3 Japan Artificial Intelligence In Cardiology Market by Medical Condition
10.3 India Artificial Intelligence In Cardiology Market
10.3.1 India Artificial Intelligence In Cardiology Market by Component
10.3.2 India Artificial Intelligence In Cardiology Market by Application
10.3.3 India Artificial Intelligence In Cardiology Market by Medical Condition
10.4 South Korea Artificial Intelligence In Cardiology Market
10.4.1 South Korea Artificial Intelligence In Cardiology Market by Component
10.4.2 South Korea Artificial Intelligence In Cardiology Market by Application
10.4.3 South Korea Artificial Intelligence In Cardiology Market by Medical Condition
10.5 Singapore Artificial Intelligence In Cardiology Market
10.5.1 Singapore Artificial Intelligence In Cardiology Market by Component
10.5.2 Singapore Artificial Intelligence In Cardiology Market by Application
10.5.3 Singapore Artificial Intelligence In Cardiology Market by Medical Condition
10.6 Malaysia Artificial Intelligence In Cardiology Market
10.6.1 Malaysia Artificial Intelligence In Cardiology Market by Component
10.6.2 Malaysia Artificial Intelligence In Cardiology Market by Application
10.6.3 Malaysia Artificial Intelligence In Cardiology Market by Medical Condition
10.7 Rest of Asia Pacific Artificial Intelligence In Cardiology Market
10.7.1 Rest of Asia Pacific Artificial Intelligence In Cardiology Market by Component
10.7.2 Rest of Asia Pacific Artificial Intelligence In Cardiology Market by Application
10.7.3 Rest of Asia Pacific Artificial Intelligence In Cardiology Market by Medical Condition
Chapter 11. Company Profiles
11.1 IDOVEN S.L.
11.1.1 Company Overview
11.2 Ultromics Ltd.
11.2.1 Company Overview
11.2.2 Recent Strategies and Developments
11.2.2.1 Partnerships, Collaborations, and Agreements
11.2.2.2 Product Launches and Product Expansions
11.3 CardiAI Inc.
11.3.1 Company Overview
11.4 Tempus AI, Inc.
11.4.1 Company Overview
11.4.2 Financial Analysis
11.4.3 Research & Development Expenses
11.4.4 Recent Strategies and Developments
11.4.4.1 Product Launches and Product Expansions
11.4.4.2 Acquisition and Mergers
11.4.5 SWOT Analysis
11.5 Koninklijke Philips N.V.
11.5.1 Company Overview
11.5.2 Financial Analysis
11.5.3 Segmental and Regional Analysis
11.5.4 Research & Development Expense
11.5.5 Recent Strategies and Developments
11.5.5.1 Partnerships, Collaborations, and Agreements
11.5.5.2 Product Launches and Product Expansions
11.5.5.3 Acquisition and Mergers
11.5.6 SWOT Analysis
11.6 Cleerly, Inc.
11.6.1 Company Overview
11.6.2 Recent Strategies and Developments
11.6.2.1 Partnerships, Collaborations, and Agreements
11.7 Vista AI, Inc.
11.7.1 Company Overview
11.8 Viz.ai, Inc.
11.8.1 Company Overview
11.8.2 Recent Strategies and Developments
11.8.2.1 Partnerships, Collaborations, and Agreements
11.8.2.2 Product Launches and Product Expansions
11.9 RSIP Vision Ltd.
11.9.1 Company Overview
11.10. GE HealthCare Technologies, Inc.
11.10.1 Company Overview
11.10.2 Financial Analysis
11.10.3 Segmental and Regional Analysis
11.10.4 Research & Development Expenses
11.10.5 Recent Strategies and Developments
11.10.5.1 Product Launches and Product Expansions
11.10.6 SWOT Analysis

Companies Mentioned

  • IDOVEN S.L.
  • Ultromics Ltd.
  • CardiAI.Inc.
  • Tempus AI, Inc.
  • Koninklijke Philips N.V.
  • Cleerly, Inc.
  • Vista AI, Inc.
  • Viz.ai, Inc.
  • RSIP Vision Ltd.
  • GE HealthCare Technologies, Inc.